Literature DB >> 16801440

Risk factors for isolation of strains susceptible only to polymyxin among patients with Pseudomonas aeruginosa bacteremia.

Matthew E Falagas1, Patra K Koletsi, Petros Kopterides, Argyris Michalopoulos.   

Abstract

We conducted a case-control study to identify risk factors associated with the isolation of Pseudomonas aeruginosa strains susceptible only to polymyxin from blood by comparing data between 16 patients with blood isolates that were susceptible only to polymyxins and 40 patients with blood isolates that were susceptible to carbapenems. The multivariable analysis showed that exposure to carbapenems was associated with the development of P. aeruginosa bacteremia susceptible only to polymyxin (odds ratio, 9.0; 95% confidence interval, 2.4 to 34.3; P = 0.001).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16801440      PMCID: PMC1489788          DOI: 10.1128/AAC.00224-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms.

Authors:  K Poole
Journal:  J Mol Microbiol Biotechnol       Date:  2001-04

Review 2.  Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review.

Authors:  A D Harris; T B Karchmer; Y Carmeli; M H Samore
Journal:  Clin Infect Dis       Date:  2001-03-21       Impact factor: 9.079

Review 3.  Methodologic issues of case-control studies: a review of established and newly recognized limitations.

Authors:  Erika M C D'Agata
Journal:  Infect Control Hosp Epidemiol       Date:  2005-04       Impact factor: 3.254

4.  Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli.

Authors:  Anthony D Harris; Matthew H Samore; Marc Lipsitch; Keith S Kaye; Eli Perencevich; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2002-05-23       Impact factor: 9.079

5.  Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B.

Authors:  S Bratu; J Quale; S Cebular; R Heddurshetti; D Landman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-03       Impact factor: 3.267

Review 6.  Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.

Authors:  G M Rossolini; E Mantengoli
Journal:  Clin Microbiol Infect       Date:  2005-07       Impact factor: 8.067

7.  Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa.

Authors:  A Deplano; O Denis; L Poirel; D Hocquet; C Nonhoff; B Byl; P Nordmann; J L Vincent; M J Struelens
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

8.  Overview of nosocomial infections caused by gram-negative bacilli.

Authors:  Robert Gaynes; Jonathan R Edwards
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079

  8 in total
  6 in total

1.  Minocycline attenuates colistin-induced neurotoxicity via suppression of apoptosis, mitochondrial dysfunction and oxidative stress.

Authors:  Chongshan Dai; Giuseppe D Ciccotosto; Roberto Cappai; Yang Wang; Shusheng Tang; Xilong Xiao; Tony Velkov
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

Review 2.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

3.  Carbapenem-resistant Pseudomonas aeruginosa: factors influencing multidrug-resistant acquisition in non-critically ill patients.

Authors:  C Peña; C Suarez; F Tubau; A Dominguez; M Sora; M Pujol; F Gudiol; J Ariza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-10-24       Impact factor: 3.267

4.  Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections.

Authors:  G Samonis; K Z Vardakas; D P Kofteridis; D Dimopoulou; A M Andrianaki; I Chatzinikolaou; E Katsanevaki; S Maraki; M E Falagas
Journal:  Infection       Date:  2014-06-10       Impact factor: 3.553

Review 5.  Current treatment of pseudomonal infections in the elderly.

Authors:  Georgios Pappas; Kaiti Saplaoura; Matthew E Falagas
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

6.  Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections.

Authors:  Nattawan Palavutitotai; Anupop Jitmuang; Sasima Tongsai; Pattarachai Kiratisin; Nasikarn Angkasekwinai
Journal:  PLoS One       Date:  2018-02-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.